HIV Citation List: November 9 - November 20, 2012

PubMed citations

1. Design of a Novel Cyclotide-cased CXCR4 Antagonist with anti-Human Inmmunodeficiency Virus (HIV)-1 Activity. Aboye, T.L., H. Ha, S. Majumder, F. Christ, Z. Debyser, A. Shekhtamn, N. Neamati, and J.A. Camarero. Journal of Medicinal Chemistry, 2012. [Epub ahead of print]; PMID[23151033]. [PubMed]. HIV_1109-112012.

2. In Vitro Effects of the CCR5 Inhibitor Maraviroc on Human T Cell Function. Arberas, H., A.C. Guardo, M.E. Bargallo, M.J. Maleno, M. Calvo, J.L. Blanco, F. Garcia, J.M. Gatell, and M. Plana. The Journal of Antimicrobial Chemotherapy, 2012. [Epub ahead of print]; PMID[23152485].

[PubMed]. HIV_1109-112012.

3. A Rationally Engineered anti-HIV Peptide Fusion Inhibitor with Greatly Reduced Immunogenicity. Brauer, F., K. Schmidt, R.C. Zahn, C. Richter, H.H. Radeke, J.E. Schmitz, D. von Laer, and L. Egerer. Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[23147734].

[PubMed]. HIV_1109-112012.

4. Impact of Sustained RNAi-Mediated Suppression of Cellular Cofactor Tat-SF1 on HIV-1 Replication in Cd4+ T Cells. Green, V.A., P. Arbuthnot, and M.S. Weinberg. Virology Journal, 2012. 9(1): p. 272. PMID[23153325].

[PubMed]. HIV_1109-112012.

5. Trimeric GPI-Anchored HCDR3 of Broadly Neutralizing Antibody PG16 Is a Potent HIV-1 Entry Inhibitor. Liu, L., W. Wang, L. Yang, H. Ren, J.T. Kimata, and P. Zhou. Journal of Virology, 2012. [Epub ahead of print]; PMID[23152526].

[PubMed]. HIV_1109-112012.

6. Effect of Early Anti-retroviral Therapy on the Pathogenic Changes in Mucosal Tissues of SIV Infected Rhesus macaques. Malzahn, J., C. Shen, L. Caruso, P. Ghosh, S. Ramachandra Sankapal, S. Barratt-Boyes, P. Gupta, and Y. Chen. Virology Journal, 2012. 9(1): p. 269. PMID[23150992].

[PubMed]. HIV_1109-112012.

7. Rational Design of Potent Non-nucleoside Inhibitors of HIV Reverse Transcriptase. Peat, A.J., P.Y. Chong, D.M. Garrido, H. Zhang, E. Stewart, R. Nolte, L. Wang, R.G. Ferris, M. Edelstein, K.L. Weaver, A. Mathis, M. Youngman, and P. Sebahar. Journal of Medicinal Chemistry, 2012. [Epub ahead of print]; PMID[23137340].

[PubMed]. HIV_1109-112012.

8. A Phenyl-thiadiazolylidene-amine Derivative Ejects Zinc from Retroviral Nucleocapsid Zinc Fingers and Inactivates HIV Virions. Vercruysse, T., B. Basta, W. Dehaen, N. Humbert, J. Balzarini, F. Debaene, S. Sanglier-Cianferani, C. Pannecouque, Y. Mely, and D. Daelemans. Retrovirology, 2012. 9(1): p. 95. PMID[23146561].

[PubMed]. HIV_1109-112012.

ISI Web of Knowledge Citations

9. Anti-HIV and Immune Modulating Activities of IND02. Biedma, M.E., B. Connell, S. Schmidt, H. Lortat-Jacob, C. Moog, and E. Prakash. Retrovirology, 2012. 9(Suppl 2): p. P220. ISI[000309472100293].

[WOS]. HIV_1109-112012.

10. The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors. Chong, H.H., X. Yao, J.P. Sun, Z.L. Qiu, M. Zhang, S. Waltersperger, M.T. Wang, S. Cui, and Y.X. He. Journal of Biological Chemistry, 2012. 287(41): p. 34558-34568. ISI[000309654200059].

[WOS]. HIV_1109-112012.

11. A Short Segment in the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Neutralization Resistance to PG9-Like Antibodies. Doria-Rose, N.A., I. Georgiev, R.P. Staupe, S. O'Dell, G. Chuang, J. Gorman, J.S. McLellan, M. Pancera, M. Bonsignori, B.F. Haynes, D.R. Burton, W.C. Koff, P.D. Kwong, and J.R. Mascola. Retrovirology, 2012. 9(Suppl 2): p. O29. ISI[000309472100030].

[WOS]. HIV_1109-112012.

12. Anti-gp41 Antibodies Inhibit Infection and Transcytosis of HIV-1 Infectious Molecular Clones Expressing Transmitted/Founder Envelopes. Jain, S., C. Ochsenbauer, J.C. Kappes, and K.L. Rosenthal. Retrovirology, 2012. 9(Suppl 2): p. P195. ISI[000309472100268].

[WOS]. HIV_1109-112012.

13. Inhibition of HIV-1 Subtype C by 2 ' F-RNA Aptamers Isolated against Enveloped Pseudovirus. London, G.G., M.M. Madiga, E.E. Gray, D.D. Sok, L.L. Morris, D.D. Burton, and M.M. Khati. Retrovirology, 2012. 9(Suppl 2):P222. ISI[000309472100295].

[WOS]. HIV_1109-112012.

14. Neutralizing anti-HIV Antibodies Develop in a Humanized Mouse Model of HIV-1 Infection. Seung, E., A. Dugast, T. Dudek, H. Mattoo, V. Vrbanac, T. Tivey, T. Murooka, A. Cariappa, A.D. Luster, S. Pillai, and A.M. Tager. Retrovirology, 2012. 9(Suppl 2): p. P60. ISI[000309472100133].

[WOS]. HIV_1109-112012.

15. A Laccase with Antiproliferative and HIV-I Reverse Transcriptase Inhibitory Activities from the Mycorrhizal Fungus Agaricus placomyces. Sun, J., Q.J. Chen, Q.Q. Cao, Y.Y. Wu, L.J. Xu, M.J. Zhu, T.B. Ng, H.X. Wang, and G.Q. Zhang. Journal of Biomedicine and Biotechnology, 2012. 2012: 736472. ISI[000309777600001].

[WOS]. HIV_1109-112012.

16. A Role for microRNA-155 Modulation in the anti-HIV-1 Effects of Toll-like Receptor 3 Stimulation in Macrophages. Swaminathan, G., F. Rossi, L.J. Sierra, A. Gupta, S. Navas-Martin, and J. Martin-Garcia. Plos Pathogens, 2012. 8(9): e1002937. ISI[000309816500037].

[WOS]. HIV_1109-112012.

17. Purification and Characterization of anti-HIV-1 Protein from Canna indica L. Leaves. Thepouyporn, A., C. Yoosook, W. Chuakul, K. Thirapanmethee, C. Napaswad, and C. Wiwat. Southeast Asian Journal of Tropical Medicine and Public Health, 2012. 43(5): p. 1153-1160. ISI[000309639500010].

[WOS]. HIV_1109-112012.

18. Methamphetamine Activates Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-kappa B) and Induces Human Immunodeficiency Virus (HIV) Transcription in Human Microglial Cells. Wires, E.S., D. Alvarez, C. Dobrowolski, Y. Wang, M. Morales, J. Karn, and B.K. Harvey. Journal of Neurovirology, 2012. 18(5): p. 400-410. ISI[000309662500006].

[WOS]. HIV_1109-112012.

19. New Aryl-1,3-thiazole-4-carbohydrazides, Their 1,3,4-oxadiazole-2-thione, 1,2,4-triazole, Isatin-3-ylidene and Carboxamide Derivatives. Synthesis and anti-HIV Activity. Zia, M., T. Akhtar, S. Hameed, and N.A. Al-Masoudi. Zeitschrift Fur Naturforschung Section B-A. Journal of Chemical Sciences, 2012. 67(7): p. 747-758. ISI[000309629500011].

[WOS]. HIV_1109-112012.